| Drug Name |
Tenofovir disoproxil fumarate |
| Drug ID |
BADD_D02156 |
| Description |
Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name _Viread_, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). This drug is prescribed in combination with other drugs for the management of HIV infection as well as for Hepatitis B therapy. Tenofovir disoproxil was initially approved in 2001 [FDA label]. |
| Indications and Usage |
Tenofovir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older. It is also indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older. |
| Marketing Status |
Prescription |
| ATC Code |
J05AF07 |
| DrugBank ID |
DB00300
|
| KEGG ID |
D01982
|
| MeSH ID |
D000068698
|
| PubChem ID |
5486830
|
| TTD Drug ID |
D0R3FP
|
| NDC Product Code |
65862-397; 66406-0103; 63285-735; 68668-351; 53104-7654; 68554-0031; 65862-421; 16714-820; 14799-2022; 60505-4666; 69076-105; 33342-501; 70518-1002; 69097-533; 65015-833; 61958-0404; 53808-1128; 61958-0403; 61958-0406; 50268-758; 61958-0401; 47234-0401; 64380-714; 63285-736; 63285-737; 67835-0020; 50683-0289; 65015-667; 70518-2151; 42291-800; 65862-819; 65862-818; 65862-820; 14593-946; 61958-0405; 70966-0023; 52562-020; 42385-741; 59997-0002; 31722-535; 42931-101; 65015-835; 76302-004; 63285-872 |
| Synonyms |
Tenofovir | 9-(2-Phosphonylmethoxypropyl)adenine | 9-PMPA (tenofovir) | 9-(2-Phosphonomethoxypropyl)adenine | 9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer | 9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer | Tenofovir Disoproxil Fumarate | Disoproxil Fumarate, Tenofovir | Fumarate, Tenofovir Disoproxil | Tenofovir Disoproxil | Disoproxil, Tenofovir | 9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098 | (R)-9-(2-phosphonylmethoxypropyl)adenine | Viread |
